AVEO Pharmaceuticals (AVEO) Stock Price Down 0%

Shares of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) dropped 0% on Tuesday . The stock traded as low as $2.82 and last traded at $2.84. Approximately 4,235,042 shares changed hands during mid-day trading, an increase of 145% from the average daily volume of 1,726,184 shares. The stock had previously closed at $2.84.

AVEO has been the subject of several research analyst reports. initiated coverage on AVEO Pharmaceuticals in a report on Wednesday, November 15th. They issued a “buy” rating and a $5.00 price objective for the company. B. Riley began coverage on AVEO Pharmaceuticals in a report on Monday, November 13th. They issued a “buy” rating and a $5.00 price objective for the company. Seaport Global Securities reaffirmed a “buy” rating on shares of AVEO Pharmaceuticals in a report on Friday, October 6th. Zacks Investment Research raised AVEO Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, January 9th. Finally, BidaskClub lowered AVEO Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Tuesday, January 9th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. AVEO Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $4.05.

The company has a market cap of $335.99, a price-to-earnings ratio of -4.00 and a beta of 1.14. The company has a current ratio of 2.33, a quick ratio of 2.33 and a debt-to-equity ratio of -0.32.

AVEO Pharmaceuticals (NASDAQ:AVEO) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.02) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.05) by $0.03. equities analysts anticipate that AVEO Pharmaceuticals, Inc. will post -0.66 EPS for the current fiscal year.

Large investors have recently bought and sold shares of the company. Fore Research & Management LP bought a new position in shares of AVEO Pharmaceuticals during the second quarter valued at approximately $111,000. Victory Capital Management Inc. bought a new position in shares of AVEO Pharmaceuticals during the third quarter valued at approximately $164,000. Rehmann Capital Advisory Group bought a new position in shares of AVEO Pharmaceuticals during the third quarter valued at approximately $193,000. OxFORD Asset Management LLP bought a new position in shares of AVEO Pharmaceuticals during the third quarter valued at approximately $228,000. Finally, Essex Investment Management Co. LLC bought a new position in shares of AVEO Pharmaceuticals during the third quarter valued at approximately $550,000. 50.91% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “AVEO Pharmaceuticals (AVEO) Stock Price Down 0%” was originally reported by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another website, it was illegally stolen and republished in violation of U.S. and international copyright law. The legal version of this article can be viewed at https://www.com-unik.info/2018/01/17/aveo-pharmaceuticals-aveo-stock-price-down-0.html.

AVEO Pharmaceuticals Company Profile

AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit